Photo from David Steensma/X
Nov 30, 2023, 15:29
David Steensma: Randomized STIMULUS-MDS1 trial didn’t meet endpoint
David Steensma, Associate professor at Harvard Medical School and faculty member in the leukemia program at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, shared a post on X/Twitter:
“Our X2105 sabatolimab (MBG453, anti-TIM3 MoAb)+HMA trial in MDSsm and CMML led by Andrew Brunner and Andrew Wei just published American Journal of Hematology. Randomized STIMULUS-MDS1 trial didn’t meet endpoint; results of larger randomized STIMULUS-MDS2 OS trial are awaited.”
For details click here.
Source: David Steensma/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 10:18
Nov 19, 2024, 10:05
Nov 19, 2024, 09:53
Nov 19, 2024, 09:44
Nov 19, 2024, 09:40
Nov 19, 2024, 09:28